Characteristics of patients with recurrent retinoblastoma: a survival analysis
- PMID: 38438837
- PMCID: PMC10910724
- DOI: 10.1186/s12885-024-12058-3
Characteristics of patients with recurrent retinoblastoma: a survival analysis
Abstract
Background: Management guidelines and corresponding survival data for patients with recurrent retinoblastoma (RB) are lacking. This study aimed to summarize the clinical characteristics of patients with recurrent RB and analyze their survival outcomes.
Methods: We retrospectively analyzed 68 patients with recurrent RB who underwent treatment in our institution from January 2016 to December 2020. Patients were grouped according to location of recurrence: intraocular, orbital, and distant metastasis.
Results: The male:female ratio was 1.3:1 and the median age at recurrence was 37.5 months (range, 30.3-62.8). The number of patients in the intraocular recurrence, orbital recurrence, and metastasis groups was 13 (19.1%), 23 (33.8%), and 32 (47.1%), respectively. Thirty patients died, 36 were alive at last follow-up, and two were lost to follow-up. Eye enucleation was performed in 94.1% of patients. Five-year overall survival in patients with intraocular recurrence, orbital recurrence, and metastasis was 84.6%, 69.6%, and 31.3%, respectively (P = 0.001). Most deaths occurred within 2 years of recurrence. Presence of high-risk pathological factors, central nervous system invasion, and absence of combination therapy were independent predictors of worse 5-year overall survival.
Conclusion: The rate of eye preservation in survivors of recurrent RB was very low. Although 5-year overall survival in patients who underwent treatment for intraocular and orbital recurrence was high, it was low in those with metastasis. RB patients may need lifelong follow-up for recurrence and secondary malignancy.
Keywords: Recurrence; Retinoblastoma; Survival analysis.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Case report: Delayed retinoblastoma relapse in a lymph node after 9 years of complete remission.Curr Probl Cancer. 2021 Oct;45(5):100703. doi: 10.1016/j.currproblcancer.2020.100703. Epub 2021 Jan 8. Curr Probl Cancer. 2021. PMID: 33618927
-
Enucleation vs Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma: A Retrospective Analysis.JAMA Ophthalmol. 2015 Sep;133(9):1062-6. doi: 10.1001/jamaophthalmol.2015.2243. JAMA Ophthalmol. 2015. PMID: 26181236 Free PMC article.
-
[Clinical analysis of orbital exenteration for orbital retinoblastoma].Zhonghua Yan Ke Za Zhi. 2014 Oct;50(10):733-6. Zhonghua Yan Ke Za Zhi. 2014. PMID: 25547574 Chinese.
-
The Results of Pars Plana Vitrectomy in the Treatment of Intraocular Retinoblastoma: A Retrospective Study and Literature Review.Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211048634. doi: 10.1177/15330338211048634. Technol Cancer Res Treat. 2021. PMID: 34747279 Free PMC article. Review.
-
Survival in extra-orbital metastatic retinoblastoma:treatment results.Clin Transl Oncol. 2006 Jan;8(1):39-44. doi: 10.1007/s12094-006-0093-x. Clin Transl Oncol. 2006. PMID: 16632438 Review.
Cited by
-
Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy.Front Pediatr. 2025 Jan 17;12:1509645. doi: 10.3389/fped.2024.1509645. eCollection 2024. Front Pediatr. 2025. PMID: 39895987 Free PMC article.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources